The Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer syndrome determined by heterozygous germline mutations in the tumor suppressor gene TP53 (chromosome 17p13). TP53 codes for a transcription factor activated in response to various stress signals and implicated in cell proliferation, apoptosis, and genomic stability. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.